Parry 2010.
Methods | Randomized, dose‐escalation |
Participants | United States N = 18 (15 mg/day: 7, 30 mg/day: 4, 50 mg/day: 7) Mean age 48.9 years (15 mg/d), 58.3 years (30 mg/d), 56.6 years (50 mg/d) Gender distribution, male (%): 57.1% (15 mg/d), 50% (30 mg/d), 57.1% (50 mg/d) Family history of ALS not reported in published manuscript |
Interventions | Ursodeocycholic acid 15 mg/day, 30 mg/day and 50 mg/day |
Outcomes | Primary: safety and tolerability |
Notes | Funded by Axcan Pharma Inc. |